STOCK TITAN

Immuneering Corp - IMRX STOCK NEWS

Welcome to our dedicated news page for Immuneering (Ticker: IMRX), a resource for investors and traders seeking the latest updates and insights on Immuneering.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Immuneering's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Immuneering's position in the market.

Rhea-AI Summary
Immuneering Corporation (IMRX) will participate in two February investor conferences to discuss the company’s pipeline, platform, and business strategy. The company aims to develop universal-RAS/RAF medicines for broad cancer patient populations. Participating will be the CEO, CSO, CBO, and CAO, discussing the company's progress and future plans. The conferences include Guggenheim 6th Annual Biotechnology Conference and Oppenheimer 34th Annual Healthcare Life Sciences Conference, with live webcasts available on Immuneering’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
none
-
Rhea-AI Summary
Immuneering Corporation (IMRX) has received FDA clearance for its Investigational New Drug (IND) application for IMM-6-415, paving the way for a Phase 1/2a clinical trial for the treatment of advanced RAF or RAS mutant solid tumors. The company expects to dose the first patient in early 2024. IMM-6-415 is a deep cyclic inhibitor of the MAPK pathway with unique drug-like properties and has shown promising preclinical single-agent and combination anti-tumor activity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.11%
Tags
-
Rhea-AI Summary
Immuneering Corporation (Nasdaq: IMRX) will present at the 35th Annual Piper Sandler Healthcare Conference to discuss the company’s pipeline, platform, and business strategy. The presentation will feature key executives and will be webcast live and archived on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.45%
Tags
conferences
Rhea-AI Summary
IMRX: Immuneering Corporation Reports Progress on IMM-1-104 Phase 1/2a Trial, Expanded Clinical Development Plan, and Financial Results for Q3 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
-
Rhea-AI Summary
Immuneering presents encouraging preclinical data for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.92%
Tags
-
Rhea-AI Summary
Immuneering Corporation will present preclinical data on its lead clinical-stage program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The data includes predicting activity of IMM-1-104 as a single agent and in combination for patients with RAS or RAF mutant tumors, as well as the anti-tumor activity and tolerability of IMM-6-415 in RAF mutant tumors. The abstracts will be available on the conference website and the posters will be available on Immuneering's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.78%
Tags
conferences clinical trial
Rhea-AI Summary
Immuneering Corporation to present at Morgan Stanley Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.74%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.86%
Tags
conferences
Immuneering Corp

Nasdaq:IMRX

IMRX Rankings

IMRX Stock Data

61.49M
15.65M
29.55%
42.35%
9.82%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Cambridge